GPE – Page 25 – Talk Bio

Bristol Myers Squibb to Cut Over 860 Jobs in New Jersey as Part of $1.5 Billion Savings Campaign

1 year ago talkbio0Tagged Drug Industry, Financial cost, Financial savings, Myers, New Jersey, savings campaign, squibb

Bristol Myers Squibb, job cuts, New Jersey, $1.5 billion savings campaign, cost savings, pharmaceutical industry

Lilly Touts Fibrosis Win, Strengthens Case for Tirzepatide in MASH Treatment

1 year ago talkbio0Tagged Diabetes, Eli, Eli Lilly, Fibrosis, GLP-1/GIP Dual Agonist, Liver diseases, MASH, Obesity, tirzepatide

Eli Lilly, Tirzepatide, MASH, Fibrosis, Liver Disease, Obesity, Diabetes, GLP-1/GIP Dual Agonist

ITM Secures €188 Million to Enhance Radiopharmaceutical Pipeline and Strengthen Medical Radioisotope Manufacturing

1 year ago talkbio0Tagged actinium-225, Authority, BlackRock, cancer pipeline, Gastro-enteropancreatic neuroendocrine tumor, Investments, Isotopes, medical radioisotopes, Munich, Qatar, Radiopharmaceuticals, SLC22A18 gene, Technology, Temasek

ITM Isotope Technologies Munich, radiopharmaceutical biotech, Temasek, BlackRock, Qatar Investment Authority, medical radioisotopes, Lutetium-177, Actinium-225, cancer pipeline, gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

GSK Strengthens Case for Blenrep’s Return in Multiple Myeloma Treatment

1 year ago talkbio0Tagged Antibody-Drug Conjugates, ASCO, Blenrep, CAR-T, Darzalex, DREAMM-7, DREAMM-8, Multiple Myeloma, Pomalyst, SmithKline Beecham, Velcade

Blenrep, GSK, multiple myeloma, ASCO, DREAMM-8, DREAMM-7, Velcade, Darzalex, Pomalyst, CAR-T therapy, antibody-drug conjugate

Annexon Shares Soar as ANX005 Meets Primary Endpoint in Phase 3 Trial for Guillain-Barré Syndrome

1 year ago talkbio0Tagged Annexon, ANX005, Disability, Guillain-Barre Syndrome, Phase 3 trial, Prices, Primary Endpoint, Sharing (Social Behavior), surge

Annexon, ANX005, Guillain-Barré Syndrome, Phase 3 Trial, Primary Endpoint, Disability Reduction, Share Price Surge

Intellia Therapeutics Reports Promising Long-Term Data for Single-Dose HAE Therapy

1 year ago talkbio0Tagged Angioedemas, Hereditary, Clustered Regularly Interspaced Short Palindromic Repeats, Gene Modification, Intellia, Long-term, NTLA-2002, single-dose

Intellia Therapeutics, NTLA-2002, Hereditary Angioedema (HAE), CRISPR Gene Editing, Single-Dose Treatment, Long-Term Data

CSL Seqirus Secures Fourth US Award to Enhance Bird Flu Vaccine Stockpile

1 year ago talkbio0Tagged Aves, BARDA, bird flu vaccine, CSHL1 gene, Government, Influenza in Birds, pandemic preparedness, public health protection, Seqirus, U.S., Vaccines

CSL Seqirus, bird flu vaccine, US government award, BARDA, pandemic preparedness, avian influenza, H5N1, vaccine stockpile, public health protection

Eli Lilly Invests $5.3 Billion in Indiana Plant to Boost Diabetes and Obesity Drug Production ###

1 year ago talkbio0Tagged alpha 1-antitrypsin, Diabetes, Eli, Eli Lilly, Glucagon-Like Peptide 1, Indiana, Manufacture, Mounjaro, Nordisk, Obesity, Zepbound

Eli Lilly, Diabetes, Obesity, Mounjaro, Zepbound, Tirzepatide, Indiana, Manufacturing, API, Novo Nordisk, GLP-1 drugs

Takeda Announces 641 Layoffs in Massachusetts Amid $900 Million Restructuring Campaign

1 year ago talkbio0Tagged Cambridge, Lexington, Massachusetts (geographic location), restructuring, Takeda

Takeda, layoffs, Massachusetts, restructuring, pharmaceuticals, biotech, Cambridge, Lexington

Innovent to Submit IL-23 Psoriasis Drug to Chinese Regulators Following Phase 3 Success

1 year ago talkbio0Tagged China, CLEAR-1, Clinical Research, Dental Plaque, Innovent, interleukin-23, picankibart, Psoriasis, regulatory

Innovent, IL-23, psoriasis, picankibart, phase 3, China, regulatory submission, plaque psoriasis, CLEAR-1 study